Blood samples (n = 5 non-FRDA controls, and n = 5 FRDA patients) were purified by immunoprecipitation (IP) using a commercial anti-human frataxin mAb and further analyzed by western blot. This evidence concerns the gene FXN and Friedreich ataxia.